Combination of 5-fluorouracil, adriamycin, ifosfamide and cisplatin in metastatic adult soft tissue sarcoma: Results of a phase II study

Oncology (Switzerland)

Volumn 53, Issue 1, 1996, Pages 58-63

  Jager E ^a   Klein, O ^a   Wachter B ^a   Bernhard, H ^b   Dippold, W ^b   Meyer zum Buschenfelde K H ^b   Knuth, Alexander ^a  

^a KRANKENHAUS NORDWEST   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Advanced soft tissue sarcoma; Combination chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; INFUSION FLUID; ONDANSETRON;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONJUNCTIVITIS; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MYCOSIS; NAUSEA; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SKIN DEFECT; SOFT TISSUE SARCOMA; SURVIVAL TIME;

EID: 0030042087     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227536     Document Type: Article

References (21)

1. Yang JC, Glatstein EJ, Rosenberg SA, Amman KH: Sarcomas of soft tissues; in DeVita VT, Heilman S, Rosenberg SA (eds): Cancer; Principles and Practice of Oncology. Philadelphia, Lippincott, 1993, pp 1436-1489.
2. Suit HD, Mankin HJ. Wood WC, Proppe KH: Preoperative, intraoperative, and postoperative radiation in the treatment of primary soft tissue sarcoma. Cancer 1985;55:2659-2667.
3. Pastorino U, Valente M, Santoro A: Results of salvage surgery for metastatic sarcomas. Ann Oncol 1990;1:269-273.
4. Antman KH, Montella D, Rosenbaum C: Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rev 1985;69:499-504.
5. Frustaci S, Foladore S, Buonadonna A, De Paoli A, Crivellari D. Carbone A, Sorio R. Morassut S, Monfardini S: Epirubicin and ifosfamide in advanced soft tissue sarcomas. Ann Oncol 1993;4:669-672.
6. Licht JD, Mazanet R, Loehrer PJ, Gonin R, Antman KH: Phase II trial of daily oral etopo-side in the treatment of advanced soft tissue sarcoma. Cancer Chcmother Pharmacol 1994; 34:79-80.
7. Mouridsen HT, Bastholt L, Somers R: Adria-mycin versus epirubicin in advanced soft tissue sarcomas: A randomized phase ll/phase III study of the EORTC Soft Tissue and Bone Sarcomas Group. Eur J Cancer Clin Oncol 1987; 23:1477-1483.
8. Schutte J, Mouridsen HT, Stewart W: Ifosfa-midc plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. Eur J Cancer 1990;26:558-561.
9. Nguyen Bilin B, Chauvergne J, Hocke C: Analysis of a scries of sixty soft tissue sarcoma in adults treated with a cyclophosphamide-vin-cristinc-adriamycin-dacarbazine (CYVADIC) combination. Cancer Chemother Pharmacol 1985;15:82-85.
10. Elias A, Ryan L, Aisner J: Mesna, doxorubicin, ifosfamide. dacarbazine (MAID) regimen for adults with advanced sarcoma. Semin Oncol 1990;17:41-49.
11. Antman KH, Baker L, Balcerzak S: A randomized study of doxorubicin and dacarbazine ± ifosfamide and mesna in advanced sarcomas. EurJ Cancer 1991;27:Abstr. 2147.
12. Santoro A, Rousse J, Stewart W: A randomized EORTC study in advanced soft tissue sarcomas (STS): Adriamycin versus Adriamycin/ifos-famide versus CYVADIC. Proc Am Soc Clin Oncol 1990;9:Abstr. 1196.
13. Steward WP, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D. Rouesse J, Tursz T, Tueni E, van Oosterom AT, Warwick J, Grcifenberg B. Thomas D, van Glabbeke M: Granulocyte-macrophagc colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993;11:15-21.
14. Berken A: Continuous 5 day infusions of 5-fluorouracil (5FU) combined with multiple doses of multiple alkylating agents. Proc Am Soc Clin Oncol 1986;5:31.
15. Enzinger FM, Weiss SW: Soft Tissue Tumors. St Louis, Mosby, 1988.
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
17. Buys SS, Metch B, Balcerzak SP, Neefe JR. Stuckey WJ: Phase II evaluation of amonafidc in advanced sarcoma: A Southwest Oncology Group study. Cancer Invest 1994;12:399-402.
18. Grabois M, Frappaz D, Bouffet E, Carrie C, Bouhour D, Philip T, Brunat-Mentigny M: High-dose VP16 cisplatinum in soft tissue sarcoma of children. Cancer Chemothcr Pharmacol 1994;33:355-357.
19. Marina NM, Rodman J, Shema S, Bowman LC, Douglass E, Furman W, Santana VM, Hudson M, Willimas J, Meyer W, Madden T, Pratt C: Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol 1993; 11:554-560.
20. van Hoesei QG, Verweij J, Catimcl G, Clavel M, Kerbrat P, van Oosterom AT, Kerger J, Tursz T, van Glabbcke M, van Pottclsberghc C: Phase II study with docetaxel (Taxotcre) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1994;5:539-542.
21. Zalupski MM, Benedetti J, Balcerzak SP, Hutchins LF, Belt RJ, Hantel A, Goodwin JW: Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study. Invest New Drugs 1993;11:337-341.